Arch Biopartners Aktie - ARCH

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

1,80

Gebot

1,79

Fragen

1,85

Volumen

13.105

1,76 Tagesbereich 1,91

1,27 52-Wochen-Bereich 2,40

Marktkapitalisierung

116,37M

Handelsende

1,81

Handelsbeginn

1,90

Letzte Trade

100

1.8

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

9.440

Ausgegebene Aktien

64.650.000

Dividendenrendite

Kurs-Gewinn-Verhältnis

-29,70

Gewinn pro Aktie (EPS)

-0,06

Erlöse

2,12M

Nettogewinn

-3,92M

Sektor

Coml Physical, Biologcl Resh

Branche

Advertising Agencies

Hauptsitz

Toronto, Ontario, Can

Gegründet

2010

Arch Biopartners Inc is listed in the Coml Physical, Biologcl Resh sector of the TSX Venture Börse with ticker ARCH. The last closing price for Arch Biopartners was $1,81. Over the last year, Arch Biopartners shares have traded in a share price range of $ 1,27 to $ 2,40.

Arch Biopartners currently has 64.650.000 shares in issue. The market capitalisation of Arch Biopartners is $117,02 million. Arch Biopartners has a price to earnings ratio (PE ratio) of -29.70.

Arch Biopartners Closes Non-Brokered Private Placement

TORONTO, March 14, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)

TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:...

Shares for Interest Debt Settlement

TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.06	-3.22580645161	1.86	1.91	1.74	7434	1.86029568	CS
4	-0.07	-3.74331550802	1.87	1.91	1.27	11276	1.75397762	CS
12	-0.1	-5.26315789474	1.9	1.94	1.27	9440	1.81965348	CS
26	-0.08	-4.25531914894	1.88	2.2	1.27	13105	1.90030547	CS
52	-0.59	-24.6861924686	2.39	2.4	1.27	14643	1.7864989	CS
156	-2.27	-55.773955774	4.07	4.23	0.97	18819	2.04116425	CS
260	0.9	100	0.9	5.3	0.87	26542	2.03355086	CS

ARCH - Frequently Asked Questions (FAQ)

What is the current Arch Biopartners share price?

The current share price of Arch Biopartners is $ 1,80

How many Arch Biopartners shares are in issue?

Arch Biopartners has 64.650.000 shares in issue

What is the market cap of Arch Biopartners?

The market capitalisation of Arch Biopartners is CAD 117,02M

What is the 1 year trading range for Arch Biopartners share price?

Arch Biopartners has traded in the range of $ 1,27 to $ 2,40 during the past year

What is the PE ratio of Arch Biopartners?

The price to earnings ratio of Arch Biopartners is -29,7

What is the cash to sales ratio of Arch Biopartners?

The cash to sales ratio of Arch Biopartners is 54,88

What is the reporting currency for Arch Biopartners?

Arch Biopartners reports financial results in CAD

What is the latest annual turnover for Arch Biopartners?

The latest annual turnover of Arch Biopartners is CAD 2,12M

What is the latest annual profit for Arch Biopartners?

The latest annual profit of Arch Biopartners is CAD -3,92M

What is the registered address of Arch Biopartners?

The registered address for Arch Biopartners is 545 KING ST W, TORONTO, ONTARIO, M5V 1M1

Which industry sector does Arch Biopartners operate in?

Arch Biopartners operates in the ADVERTISING AGENCIES sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
PORPortofino Resources Inc	$ 0,01 (100,00%)	100k
CPLCopper Lake Resources Ltd	$ 0,01 (100,00%)	200k
SSESilver Spruce Resources Inc	$ 0,01 (100,00%)	1,19M
ALTAlturas Minerals Corp	$ 0,01 (100,00%)	500k
ROVRRover Critical Minerals Corp	$ 0,20 (100,00%)	8,6k
JES.PJesmond Capital Ltd	$ 0,045 (-43,75%)	4k
PHDProvidence Gold Mines Inc	$ 0,035 (-36,36%)	374k
SEVSpectra7 Microsystems Inc	$ 0,01 (-33,33%)	101,3k
EPO.HEncanto Potash Corp	$ 0,03 (-33,33%)	361,91k
INFMInfinico Metals Corp	$ 0,01 (-33,33%)	592k
AMXAmex Exploration Inc	$ 1,03 (14,44%)	2,79M
MJSMajestic Gold Corp	$ 0,11 (4,76%)	2,33M
SIESienna Resources Inc	$ 0,03 (-14,29%)	2,2M
FYLFinlay Minerals Ltd	$ 0,115 (53,33%)	1,83M
BONEBoron One Holdings Inc	$ 0,035 (-12,50%)	1,45M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Arch Biopartners Inc (ARCH) Börsenkurse

Arch Biopartners Inc (ARCH)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Arch Biopartners Inc

ARCH Neueste Nachrichten

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)

Shares for Interest Debt Settlement

Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Arranges Non-Brokered Private Placement

Closes Units for Debt Settlement

Units for Debt Settlement

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)

Shares for Interest Debt Settlement

Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Arranges Non-Brokered Private Placement

Closes Units for Debt Settlement

ARCH - Frequently Asked Questions (FAQ)

Beweger

ARCH Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen